Author

M. Derweduwe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Claeys· 2 shared B. Cole· 2 shared F. De Smet· 2 shared K. L. Ligon· 2 shared S. De Vleeschouwer· 2 shared A. Martinez· 1 shared B. Boeckx· 1 shared B. Decraene· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Claeys

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

L. Finotto, B. Cole, W. Giese, E. Baumann, A. Claeys, M. Vanmechelen, B. Decraene, M. Derweduwe, N. Dubroja Lakic, G. Shankar, M. Nagathihalli Kantharaju, J. P. Albrecht, I. Geudens, F. Stanchi, K. L. Ligon, , H. Gerhardt

The paper identifies LGALS1 as an immunomodulating target in glioblastoma by analyzing GAM-GBM interactions using single-cell RNA sequencing and zebrafish models.

bioRxiv · Apr 27, 2023 · PreprintCancer Biology

Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma

D. Panovska, P. Nazari, B. Cole, P.-J. Creemers, M. Derweduwe, L. Solie, S. Van Gassen, A. Claeys, T. Verbeke, Y. Saeys, D. Van Der Planken, F. M. Bosisio, E. Put, S. Bamps, P. Clement, , F. De Smet

The paper introduces PROSPERO, a single-cell assay to evaluate therapy response in glioblastoma by measuring molecular drug responses in fresh tumor samples, revealing limited therapeutic capacity and cellular plasticity.

bioRxiv · Oct 17, 2022 · PreprintCancer Biology